The cost challenge in CAR-T manufacturing: Physical and chemical methods to optimize transduction and lower costs

High viral vector costs can limit the scalability and affordability of CAR-T manufacturing. This literature review highlights a study from Silva Couto et al. published in Molecular Therapy Advances that systematically evaluates physical and chemical methods to optimize lentiviral transduction and lower costs of CAR-T therapy manufacturing.

Read the literature review to learn more about how to:

• Increase CAR expression: See how some transduction enhancers can increased CAR expression.
• Optimize key process parameters: Apply evidence-based spinoculation settings to improve transduction without compromising cell growth.
• Reduce reliance on vector dose escalation: Understand why process optimization can outperform adding more vector.
• Support scalable manufacturing: Review results showing nearly doubled CAR expression in the optimized workflow, with comparable product quality and robustness across donors.

Read this literature review now.

LentiBOOST Pharma-Grade technology: For research use only. Not for use in diagnostic procedures.

LentiBOOST GMP Grade technology: Not for diagnostic use. Other applications must be authorized by a license from Revvity.